An Introduction to Chronic Cough
Chronic cough is defined as a cough that lasts longer than 8 weeks. It can seriously impair quality of life. Frequent causes include allergies, asthma, bronchitis, gastroesophageal reflux disease and lung disease. Chronic cough remains a challenge to diagnose and manage clinically, although advances in our scientific understanding of chronic cough have been made in the last decade. Novel therapeutic agents are currently in development and clinical trial results are proving promising for the treatment of this common condition.
Expert video highlights and insights from the conference hub, and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing diagnosis and treatment landscape.
Chronic Cough Content
Analysis of gefapixant efficacy and safety by history of refractory or unexplained chronic cough: Imran Satia, ERS 2023
COUGH 1 and COUGH 2, were randomized, double-blind, placebo-controlled phase 3 trials, that investigated gefapixant for the treatment of refractory or unexplained chronic cough. It was a pleasure to speak with Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) around his analysis of COUGH-1 and -2, looking at gefapixant efficacy by patient history of refractory […]
P2X3 receptor antagonists for the treatment of chronic cough: Imran Satia, ERS 2023
With limited options in the treatment paradigm for refractory or unexplained chronic cough, P2X3 receptor antagonists have shown great promise in clinical trials. We were delighted to speak to Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) to discuss the current unmet needs when treating chronic cough and the investigational P2X3 receptor antagonists currently in […]
Camlipixant: A New Treatment Option for Refractory Chronic Cough?
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(2):8–9:Online ahead of journal publication
Chronic cough is a cough that lasts 8 weeks or longer and is not due to serious underlying conditions. It is a common problem in primary care, accounting for up to 40% of referrals to pulmonologists.1 Common causes include rhinosinusitis, cough-variant asthma, eosinophilic bronchitis, smoking, certain medications (including angiotensin-converting enzyme inhibitors) and gastroesophageal reflux.2 Once serious […]
Gefapixant for the treatment of chronic cough – a dose-response analysis: Elena Kum, ERS 2023
Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, Hamilton, ON, Canada) around the aims, methodology and findings from her dose-response meta-analysis of gefapixant. […]
Foreword touchREVIEWS in Respiratory & Pulmonary Diseases Volume 8, Issue 1, 2023
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):1
Welcome to the latest issue of touchREVIEWS in Respiratory & Pulmonary Diseases, in which we bring you a range of topical and timely articles in the field of lung diseases. In this issue, we begin with an expert interview about lebrikizumab (an anti-interleukin-13 biologic) for asthma. Stanley Szefler describes the clinical trials that have helped […]
Future Directions in Chronic Cough
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):28–32 DOI: https://doi.org/10.17925/USRPD.2023.8.1.28
Chronic cough, defined as a cough lasting over 8 weeks, has an estimated global prevalence of 10% and has significant detrimental physical, social and psychological consequences on individuals.1,2 Chronic cough is a complex heterogeneous disease, in which many causative factors need to be explored (Figure 1).3 The three most reported associations are rhinosinusitis, gastro-oesophageal reflux disease and […]
Management of patients with NTM-LD: Improving adherence for optimal outcomes
Watch expert pulmonologists discuss how to optimize the diagnosis and management of patients with NTM-LD
- Appraise strategies to reduce time to diagnosis for patients with NTM-LD
- Utilize guideline recommendations when setting individualized treatment goals for patients with NTM-LD
- Apply strategies to manage adverse events for improved outcomes and adherence in patients with NTM-LD
The patient pathway to diagnosis for non-cystic fibrosis bronchiectasis
MDT specialists and a patient with non-cystic fibrosis (non-CF) bronchiectasis discuss the pathophysiology, comorbidities and the pathway to diagnosis
- Describe the pathophysiology and comorbidities of non-CF bronchiectasis
- Appraise the clinical presentations of non-CF bronchiectasis
- Analyse the methodologies to diagnose non-CF bronchiectasis
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!